JP5990029B2 - 毛髪の分析法 - Google Patents
毛髪の分析法 Download PDFInfo
- Publication number
- JP5990029B2 JP5990029B2 JP2012094042A JP2012094042A JP5990029B2 JP 5990029 B2 JP5990029 B2 JP 5990029B2 JP 2012094042 A JP2012094042 A JP 2012094042A JP 2012094042 A JP2012094042 A JP 2012094042A JP 5990029 B2 JP5990029 B2 JP 5990029B2
- Authority
- JP
- Japan
- Prior art keywords
- hair
- concentration
- serum
- cancer
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 231100000640 hair analysis Toxicity 0.000 title description 20
- 210000004209 hair Anatomy 0.000 claims description 198
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 claims description 180
- 102000043299 Parathyroid hormone-related Human genes 0.000 claims description 178
- 210000002966 serum Anatomy 0.000 claims description 153
- 210000004027 cell Anatomy 0.000 claims description 102
- 150000002500 ions Chemical class 0.000 claims description 48
- 229910001424 calcium ion Inorganic materials 0.000 claims description 38
- 210000004369 blood Anatomy 0.000 claims description 32
- 239000008280 blood Substances 0.000 claims description 32
- 229910052801 chlorine Inorganic materials 0.000 claims description 25
- 210000000170 cell membrane Anatomy 0.000 claims description 21
- 229910052791 calcium Inorganic materials 0.000 claims description 18
- 229910052698 phosphorus Inorganic materials 0.000 claims description 15
- 229910052794 bromium Inorganic materials 0.000 claims description 13
- 229910052712 strontium Inorganic materials 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 10
- -1 compound ions Chemical class 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 7
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 description 482
- 239000000460 chlorine Substances 0.000 description 172
- 206010028980 Neoplasm Diseases 0.000 description 102
- 201000011510 cancer Diseases 0.000 description 100
- 102000004310 Ion Channels Human genes 0.000 description 56
- 239000010949 copper Substances 0.000 description 56
- 238000000034 method Methods 0.000 description 46
- 239000010936 titanium Substances 0.000 description 32
- 230000003834 intracellular effect Effects 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 29
- 102000004169 proteins and genes Human genes 0.000 description 29
- 230000007423 decrease Effects 0.000 description 27
- 108020003175 receptors Proteins 0.000 description 27
- 102000005962 receptors Human genes 0.000 description 27
- 230000007812 deficiency Effects 0.000 description 23
- 238000005259 measurement Methods 0.000 description 22
- 230000008569 process Effects 0.000 description 22
- 102000004506 Blood Proteins Human genes 0.000 description 19
- 108010017384 Blood Proteins Proteins 0.000 description 19
- 208000005223 Alkalosis Diseases 0.000 description 17
- 230000002340 alkalosis Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 15
- 230000003913 calcium metabolism Effects 0.000 description 14
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 13
- 125000004429 atom Chemical group 0.000 description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
- 108090000445 Parathyroid hormone Proteins 0.000 description 11
- 102000003982 Parathyroid hormone Human genes 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000013632 homeostatic process Effects 0.000 description 11
- 230000004941 influx Effects 0.000 description 11
- 230000003908 liver function Effects 0.000 description 11
- 239000000199 parathyroid hormone Substances 0.000 description 11
- 229960001319 parathyroid hormone Drugs 0.000 description 11
- 229940085991 phosphate ion Drugs 0.000 description 11
- 208000010444 Acidosis Diseases 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 10
- 230000007950 acidosis Effects 0.000 description 10
- 208000026545 acidosis disease Diseases 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 239000010419 fine particle Substances 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000011574 phosphorus Substances 0.000 description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 8
- 230000005856 abnormality Effects 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000004876 x-ray fluorescence Methods 0.000 description 8
- 230000003915 cell function Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- 208000006386 Bone Resorption Diseases 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000024279 bone resorption Effects 0.000 description 6
- 230000006866 deterioration Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 101001053395 Arabidopsis thaliana Acid beta-fructofuranosidase 4, vacuolar Proteins 0.000 description 5
- 238000003915 air pollution Methods 0.000 description 5
- 230000005907 cancer growth Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229910052719 titanium Inorganic materials 0.000 description 5
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 4
- 239000000809 air pollutant Substances 0.000 description 4
- 231100001243 air pollutant Toxicity 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000011572 manganese Substances 0.000 description 4
- 230000008060 renal absorption Effects 0.000 description 4
- 239000004576 sand Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000011180 diphosphates Nutrition 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 208000001613 Gambling Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 208000003076 Osteolysis Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 230000009460 calcium influx Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 229910052745 lead Inorganic materials 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 230000000849 parathyroid Effects 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000000512 proximal kidney tubule Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 2
- 229910001427 strontium ion Inorganic materials 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 210000005233 tubule cell Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910017945 Cu—Ti Inorganic materials 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102100035650 Extracellular calcium-sensing receptor Human genes 0.000 description 1
- 101710159793 Extracellular calcium-sensing receptor Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010027423 Metabolic alkalosis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000002083 X-ray spectrum Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 150000001793 charged compounds Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000003803 hair density Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 230000005596 ionic collisions Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 210000005234 proximal tubule cell Anatomy 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000005469 synchrotron radiation Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012094042A JP5990029B2 (ja) | 2012-04-17 | 2012-04-17 | 毛髪の分析法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012094042A JP5990029B2 (ja) | 2012-04-17 | 2012-04-17 | 毛髪の分析法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013221866A JP2013221866A (ja) | 2013-10-28 |
| JP2013221866A5 JP2013221866A5 (https=) | 2015-06-18 |
| JP5990029B2 true JP5990029B2 (ja) | 2016-09-07 |
Family
ID=49592928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012094042A Active JP5990029B2 (ja) | 2012-04-17 | 2012-04-17 | 毛髪の分析法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5990029B2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6329821B2 (ja) * | 2014-06-17 | 2018-05-23 | 千川 純一 | 毛髪分析によるガン等に起因するカルシウム代謝異常の判別のための方法 |
| JP6946133B2 (ja) * | 2017-09-27 | 2021-10-06 | 株式会社レナテック | がんリスク評価方法及びがんリスク評価システム |
| WO2020059401A1 (ja) * | 2018-09-21 | 2020-03-26 | 小嶋 良種 | 生体液の検査方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4065734B2 (ja) * | 2002-07-10 | 2008-03-26 | 財団法人ひょうご科学技術協会 | 体調の検査方法 |
| CN100549015C (zh) * | 2002-12-05 | 2009-10-14 | Md白奥阿尔法有限公司 | 氨基酸螯合物的制备方法 |
| JP4612355B2 (ja) * | 2004-08-13 | 2011-01-12 | 純一 千川 | 毛髪又は体毛によるカルシウム代謝異常の検出方法 |
| JP2011047715A (ja) * | 2009-08-25 | 2011-03-10 | La Belle Vie Kk | 毛髪中ミネラル成分の網羅的分析に基づく癌の検出方法 |
| JP2011107113A (ja) * | 2009-11-20 | 2011-06-02 | Yoshitane Kojima | 蛍光ｘ線分析装置による体組織及び食品中の元素検査方法 |
-
2012
- 2012-04-17 JP JP2012094042A patent/JP5990029B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013221866A (ja) | 2013-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ecotière et al. | Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients | |
| Thomas et al. | Guideline for the laboratory diagnosis of functional iron deficiency. | |
| Fernández-Rodríguez et al. | Diagnosis of iron deficiency in chronic renal failure | |
| Ahluwalia et al. | Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure | |
| Wick et al. | Iron metabolism: diagnosis and therapy of anemias | |
| Gartmann et al. | Expression of zinc transporters ZIP4, ZIP14 and ZnT9 in hepatic carcinogenesis—an immunohistochemical study | |
| Sanders et al. | Prenatal and early childhood critical windows for the association of nephrotoxic metal and metalloid mixtures with kidney function | |
| EA026944B1 (ru) | Применение антитела к человеческому прогастрину для приготовления лекарственного средства для лечения колоректального рака и способы лечения метастатического колоректального рака (варианты) | |
| Mijuskovic et al. | Tissue and urinary KIM-1 relate to tumor characteristics in patients with clear renal cell carcinoma | |
| JP5990029B2 (ja) | 毛髪の分析法 | |
| WO2011089101A1 (en) | Tumor tissue based biomarkers for bevacizumab combination therapies | |
| EP2596348B1 (en) | System and method for analyzing samples labeled with 5, 10, 15, 20 tetrakis (4-carboxyphenyl) porphine (tcpp) | |
| KR20180069904A (ko) | 마커 분자를 기반으로 화학요법으로 치료되어야 하는 개체를 식별하는 방법 및 관련 용도 | |
| US20040229300A1 (en) | Zinc-based screening test and kit for early diagnosis of prostate cancer | |
| Cohney et al. | Donor renal function | |
| Chikawa et al. | A correlation of breast cancer and calcium levels in hair analyzed by X-ray fluorescence | |
| Canola et al. | Iron-related markers of inflammation in horses with colic | |
| Chung et al. | Comparison of Erythrocyte and Reticulocyte Indices for Evaluation of Iron Deficiency by Two Automated Hematologic Analyzers. | |
| JP2020020689A (ja) | 毛髪分析法 | |
| Tenório et al. | Assessment of bone metabolism biomarkers in serum and saliva of cirrhotic patients | |
| JP6329821B2 (ja) | 毛髪分析によるガン等に起因するカルシウム代謝異常の判別のための方法 | |
| Pour et al. | Alteration of pancreatic endocrine cell patterns and their secretion during pancreatic carcinogenesis in the hamster model | |
| WO2024056075A1 (zh) | 盘状结构域受体2在诊断胶质瘤中的应用及相关的计算机可读介质 | |
| Chikawa et al. | Concentration homeostasis and elements in hair and dried serum observed by x-ray fluorescence analysis using synchrotron radiation | |
| WO2010064259A1 (en) | A test kit and method for measurement of metals in biological fluids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150416 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150416 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160224 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160301 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160426 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160726 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160812 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5990029 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |